| Literature DB >> 27121424 |
Alan C Logan1,2, Felice N Jacka1,2,3,4,5,6, Jeffrey M Craig1,7, Susan L Prescott1,8.
Abstract
Relationships between gastrointestinal viscera and human emotions have been documented by virtually all medical traditions known to date. The focus on this relationship has waxed and waned through the centuries, with noted surges in interest driven by cultural forces. Here we explore some of this history and the emerging trends in experimental and clinical research. In particular, we pay specific attention to how the hygiene hypothesis and emerging research on traditional dietary patterns has helped re-ignite interest in the use of microbes to support mental health. At present, the application of microbes and their structural parts as a means to positively influence mental health is an area filled with promise. However, there are many limitations within this new paradigm shift in neuropsychiatry. Impediments that could block translation of encouraging experimental studies include environmental forces that work toward dysbiosis, perhaps none more important than westernized dietary patterns. On the other hand, it is likely that specific dietary choices may amplify the value of future microbial-based therapeutics. Pre-clinical and clinical research involving microbiota and allergic disorders has predated recent work in psychiatry, an early start that provides valuable lessons. The microbiome is intimately connected to diet, nutrition, and other lifestyle variables; microbial-based psychopharmacology will need to consider this contextual application, otherwise the ceiling of clinical expectations will likely need to be lowered.Entities:
Keywords: Allergy and Immunology; Anxiety; Depression; Diet; Human microbiome; Microbiota
Year: 2016 PMID: 27121424 PMCID: PMC4857870 DOI: 10.9758/cpn.2016.14.2.131
Source DB: PubMed Journal: Clin Psychopharmacol Neurosci ISSN: 1738-1088 Impact factor: 2.582
Fig. 1Beneficial microbes for fatigue and depression; originally proposed pathway. Adapted from references 57, 78, and 225.
Select human studies involving probiotics
| Subjects/Condition | Beneficial microbe(s) | Duration | Beneficial outcome |
|---|---|---|---|
| [131] Healthy adults (n=124) | 3 Weeks | Those in the bottom 1/3 of the group initial scores on POMS reported feeling happier and less depressed | |
| [130] Laryngeal cancer (n=20) | 2 Weeks, pre-surgery | Lowered serum corticotropin-releasing factor, heart rate; reduced HAS scores pre-surgery | |
| [132] Chronic fatigue (n=39) | 8 Weeks | Improved scores on BAI vs. baseline | |
| [135] Healthy adults (n=44) | 4 Weeks | Decreased tension-anxiety on the POMS | |
| [137] Healthy adults (n=40) | 4 Weeks | Reduced self-reported cognitive reactivity to sad mood; reduced aggressive/ruminative thoughts. Measured via Leiden Index of Depression Sensitivity | |
| [133] Healthy adults (n=55) | 4 Weeks | Lower global severity index on the Hopkins Symptom Checklist 90; Improved depression anger-hostility and somatization; lower anxiety on the HADS | |
| [136] Infants with atopy risk (n=75) | 24 Weeks post-birth | Physician-diagnosed attention-deficit hyperactivity or Asperger syndrome (ICD-10 criteria at age 13 years) is lower |
POMS, the Profile of Mood States; HAS, Hamilton Anxiety Scale; BAI, Beck Anxiety Inventory; HADS, Hospital Anxiety and Depression Scale; ICD-10, International Classification of Diseases 10th revision.